Published in final edited form as:

J Org Chem. 2013 January 4; 78(1): 3–8. doi:10.1021/jo3008226.

Crotylboron-Based Synthesis of the Polypropionate Units of Chaxamycins A/D, Salinisporamycin, and Rifamycin S

Ming Chen and William R. Roush*

Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, FL 33458

Abstract

Syntheses of the C(15)–C(27) fragments of chaxamycins A/D, rifamycin S, and the C(12)–C(24) fragment of salinisporamycin have been accomplished in ten steps from commercially available starting materials. Three crotylboron reagents were utilized to construct the seven contiguous stereocenters in these fragments with excellent stereoselectivity.

Aldehyde allylboration, synthesis of propionate fragments of chaxamycins A and D, rifamycin S and salinisporamycin

Introduction

Ansamycin antibiotics such as the rifamycins¹ are macrolides consisting of an aromatic chromophore bridged by an aliphatic chain linking two nonadjacent positions on the aromatic moiety. In addition to their antimicrobial activities against many Gram positive and some Gram-negative bacteria, many ansamycins also exhibit antiviral activities.¹ Furthermore, it is well documented that some members of the ansamycin family selectively interact with the ATP-binding pocket in the N-terminal domain of the heat shock protein 90 (Hsp90) and demonstrate antitumor activity.²

Because of the structural complexities coupled with diverse biological activities, extensive efforts have been devoted to the syntheses of ansamycin natural products. In 1980, Kishi and coworkers reported the first total synthesis of rifamycin S.³ Following his landmark work, many strategies have been developed for the synthesis of the polyketide ansa chain of rifamycin S.⁴

Recently, salinisporamycin^{5,6} and several new members of the ansamycin antibiotic family, chaxamycins A–D,⁷ were reported (Figure 1). Salinisporamycin was isolated in 2009 from *Salinispora arenicola*. Subsequent biological studies revealed that salinisporamycin not only showed antimicrobial activity, but also inhibited the growth of A549 cells (the human lung adenocarcinoma cell line) with an IC₅₀ value of 3 μg/mL.⁵ Chaxamycins A–D were isolated from *Streptomyces* sp. strain C34 obtained from soil collected in the hyper-arid Chilean Atacama Desert.⁷ Among the chaxamycins, chaxamycin D displayed a highly selective antibacterial activity against *S. aureus* ATCC 25923 with an IC₅₀ value of 0.05 μg/mL.

As illustrated in Figure 1, chaxamycins A and D have ansa chains that are very similar to the analogous fragments of salinisporamycin and rifamycin S (shown in red in Figure 1). One intriguing structural feature of these natural products is the *anti,anti*-stereotriad embedded in

*roush@scripps.edu.

Supporting Information Available. Details of stereochemical assignments and copies of ¹H and ¹³C NMR spectra of new compounds are available via the internet at <http://pubs.acs.org>.

the polyketide chain (highlighted in yellow in Figure 1). In order to access this requisite *anti,anti*-stereotriad,⁸ many creative approaches, including epoxide ring opening reactions,^{3,4k} the desymmetrization of *meso* intermediates^{4d,4l,4m} or elaboration of intermediates derived from hetero-Diels-Alder reactions,^{4f} have been developed.

In 1987, our laboratory reported a stereoselective synthesis of the ansa chain of rifamycin S^{4g,4j} using the tartrate-based crotylboronate reagents.⁹ In initial studies, we attempted a mismatched double asymmetric crotylboration¹⁰ of the β -branched chiral aldehyde **1** using our tartrate ester modified crotylboronate reagent for the synthesis of the *anti,anti*-stereotriad **A**. However, the tartrate-based crotylboronate reagent failed to override the intrinsic diastereofacial selectivity of the chiral aldehyde, and a mixture of diastereomers was obtained with the desired *anti,anti*-stereotriad **A** only as a minor product. Therefore, we pursued an alternative strategy in which the *anti,anti*-stereotriad **2**, which can be prepared with good selectivity,^{4g} was used at the starting point for the synthesis (Figure 2a).

Recently, we described highly diastereoselective syntheses of *anti,anti*-stereotriads, such as **5**, using mismatched double asymmetric δ -stannylcrotylboration reactions¹¹ of chiral aldehydes with the chiral crotylborane reagents (*R*)-(*E*)-**4** or (*S*)-(*E*)-**4**¹² (Figure 2b). Because of the exceptional enantiofacial selectivity of reagents (*S*)-(*E*)-**4** and (*R*)-(*E*)-**4**, we were intrigued whether the *anti,anti*-stereotriad within the polyketide chain segment of the structures in Figure 1 could be prepared using reagent (*R*)-(*E*)-**4** (Figure 2c). This would enable these syntheses to be accomplished in a more direct, step-wise efficient manner without resorting to the pseudo two-directional chain synthesis approach in our first generation synthesis of the rifamycin S ansa chain.^{4j} The results of this study are reported in this manuscript.

Results and Discussion

Our retrosynthetic analysis for synthesis of the polypropionate units **8** and **9** is summarized in Figure 3. We envisioned that **8** and **9** could be assembled from aldehyde **10**, crotylborane (*S*)-(*E*)-**4**¹² and vinyl iodides **11**.^{6a,13} To access the *anti,anti*-stereotriad embedded in aldehyde **10**, we planned to utilize the mismatched double asymmetric δ -stannylcrotylboration of aldehyde **13** with the chiral crotylborane reagent (*R*)-(*E*)-**4**.^{11,12}

The synthesis of aldehyde **13** is summarized in Scheme 1. Commercially available ester **14** was converted into aldehyde **15** in two steps according to known procedures.¹⁴ Crotylboration of **15** using Brown's (*Z*)-crotylborane reagent **16** gave homoallylic alcohol **17** in 81% yield.¹⁵ Protection of the secondary alcohol of **17** (TBSOTf, 2,6-lutidine) gave the known TBS ether **18** in near quantitative yield.¹⁶ Subsequent ozonolysis reaction of **18** provided aldehyde **13** in 91% yield.

Addition of aldehyde **13** to a solution of (*R*)-(*E*)-**4** (generated as described previously^{11,12}) at $-78\text{ }^{\circ}\text{C}$ followed by warming the reaction mixture to ambient temperature provided the targeted *anti,anti*-stereotriad **12** in 71% yield and with >15:1 diastereoselectivity (Scheme 2a). Subsequent protodestannylation of **12** under acidic conditions (TsOH·H₂O)^{12b} provided alcohol **19** in 92% yield.

The intrinsic diastereofacial preference of aldehyde **13** was assessed by using the crotylboration reaction with the achiral pinacol (*E*)-crotylboronate **20** (Scheme 2b). Interestingly, formation of the major isomer 3,4-*anti*-4,5-*syn*-stereotriad **21** was only slightly favored (~1.4:1) over the *anti,anti*-stereotriad **19**. The stereochemistry of the major product **21** was assigned following ozonolysis with reductive workup using NaBH₄ followed by conversion of the 1,3-diol to the corresponding acetonide, the 2,3-stereochemistry of which

was easily assigned by ^1H NMR analysis as summarized in the Supporting Information. The ratio of **21** and **19** suggests that the two competing transition states, **TS-1** and **TS-2**, which lead to the formation of **21** and **19**, respectively, must be relatively close in energy.

As shown in Scheme 2b, the slightly favored transition state **TS-1** proceeds under substrate/Felkin-Anh¹⁷ control to give the 3,4-*anti*-4,5-*syn*-stereotriad **21**. A relatively minor gauche-pentane interaction¹⁸ between the methyl group of the crotyl unit and the methyl group of aldehyde **13** occurs in **TS-1** (shown in red). On the other hand, the competing *anti*-Felkin-Anh transition state **TS-2** gives *anti,anti*-stereotriad **19**. Gauche-pentane interactions¹⁸ between the methyl group of the crotylboronate reagent and the side chain of aldehyde **13** (indicated in the red box in **TS-2**, Scheme 2b) should develop in **TS-2**. Close examination of **TS-2** reveals that the side chain of aldehyde **13** can adopt a conformation such that the secondary OTBS group is positioned away from the methyl group of the crotylboronate and only a hydrogen atom is within close proximity to the methyl group of the crotyl unit (shown in red in **TS-2**). Consequently, it appears that the Felkin-Anh **TS-1** and the *anti*-Felkin-Anh **TS-2** have comparable non-bonded steric interactions between aldehyde **13** and the achiral pinacol crotylboronate **20**. This analysis is consistent with experimental results that the two competing transition states for the crotylboration reaction are close in energy.

It is well documented that many classical chiral crotylating reagents have demonstrated ability to overcome modest intrinsic diastereofacial selectivities (e.g., < 3–4:1 ds) of chiral aldehydes.^{4j,19} Indeed, when aldehyde **13** was treated with the tartrate derived chiral crotylboronate reagent **22**,⁹ the *anti,anti*-stereotriad **19** was obtained in 72% yield and with 13:1 diastereoselectivity (Scheme 2c).

It is appreciated that the intrinsic diastereofacial selectivity preferences of chiral aldehydes in reactions with achiral crotylboron reagents (as well as with other crotylmetal reagents) is dependent on the stereochemistry of the chiral aldehyde substrate as well as the protecting groups included in the substrates (e.g., compare results of mismatched double asymmetric reactions of **1** and **13** with the tartrate ester crotylboronate, **22**, presented above).^{19d} Indeed, as summarized in Scheme 3, the crotylboration reactions of aldehydes **23**, **24**, and **25**, which are diastereomers of **13**, with achiral pinacol crotylboronate (**20**) provide product mixtures ranging from 3:1 (for **23**) to > 100:1 (for **25**). The β -alcohol protecting groups of aldehydes **24** and **25** project into space occupied by the (E)-methyl group of the crotylborane reagent in transition states **TS-4** and **TS-5** (which lead to the minor *anti, anti* stereotriads **29** and **31**, respectively), thereby destabilizing these transition states and making it difficult to access structures like **29** and **31**.²⁰ Therefore, while conventional chiral crotylmetal reagents may be capable of overriding the intrinsic diastereofacial preference of substrates such as **13** and **23** in mismatched double asymmetric reactions,¹⁹ a much more highly enantioselective reagent such as **4** is required to achieve acceptable stereochemical control in mismatched double asymmetric reactions with chiral aldehydes with intrinsic diastereofacial selectivities >5:1 (and especially >10:1).¹¹

Completion of the syntheses of **8** and **9** is summarized in Scheme 4. The secondary alcohol of stereopentad **19** was protected as a TBS ether under standard conditions (TBSOTf, 2,6-lutidine). Ozonolysis of TBS ether **32** gave aldehyde **10** in 88% yield. Matched double asymmetric crotylboration of **10** with (*S*)-(*E*)-**4** provided δ -stannyl-homoallylic alcohol **33** in 78% yield and with >15:1 diastereoselectivity. Other diastereomers were not detected in the reaction mixture. The *anti*-relative stereochemistry of two newly formed stereocenters in **33** was supported by the coupling constant analysis of the acetonide derivative **34** that was prepared from **33** by protiodestannylation, ozonolysis, reductive workup of the ozonide using NaBH_4 , and then acetonide formation (please see SI for details). Finally, a Pd-catalyzed Stille coupling²¹ of vinyl stannane **33** with vinyl iodide **11a**¹³ provided **8** in 61%

yield. Similarly, coupling of vinyl stannane **33** with vinyl iodide **11b**^{6a} afforded **9** in 68% yield under analogous reaction conditions.

Conclusion

Syntheses of the polypropionate fragments of chaxamycins A/D, salinisporamycin and rifamycin S were accomplished in ten steps from commercially available starting materials. Three crotylboron reagents were utilized to construct the seven contiguous stereocenters in these polypropionate units. The vinylstannane unit of alcohol **33** derived from the matched double asymmetric crotylboration of aldehyde **10** with crotylborane (*S*)-(*E*)-**4** allowed direct C–C bond formation using a subsequent Stille coupling reaction.²¹ Other synthetic applications of crotylborane reagents (*S*)-(*E*)-**4** and (*R*)-(*E*)-**4** will be reported in due course.

Experimental Section²²

(3R,4R,5R,6R,7R)-6,8-bis((tert-butyldimethylsilyl)oxy)-3,5,7-trimethyloct-1-en-4-ol (**19**)

A 50-mL, pear-shaped flask equipped with a rubber septum and argon inlet needle was charged with 4 Å molecular sieves (freshly activated under vacuum, 200 mg) and anhydrous toluene (15 mL). To this flask was added a solution of aldehyde **13** (750 mg, 2.0 mmol, prepared in five steps from commercially available ester **14** according to known precedures^{14–16}) in anhydrous toluene (5 mL). The mixture was then cooled to –78 °C and a solution of (*E*)-crotylboronate **22**⁹ in toluene (3.8 mL, ~0.8 M, 3.0 mmol, 1.5 equiv) was added. The mixture was kept at –78 °C and stirred for 24 h. The reaction was quenched by addition of aqueous 3 N NaOH (5 mL) and stirred vigorously for 2 h. Brine (5 mL) was added, the organic layer was separated and the aqueous layer was extracted with Et₂O (3 × 5 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification of the crude product was performed by flash column chromatography (gradient elution, hexane–Et₂O = 100:1 to 10:1), which provided *anti*, *anti*-stereotriad **19** (620 mg, 72% yield; ds = 13:1) as a colorless oil: [α]_D^{28.5} = +15.8° (c 0.75, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 5.88 (ddd, *J* = 16.8, 10.4, 8.4 Hz, 1H), 5.02–5.08 (m, 2H), 3.85 (dd, *J* = 6.4, 2.0 Hz, 1H), 3.74 (dd, *J* = 10.0, 4.8 Hz, 1H), 3.50 (ddd, *J* = 10.4, 4.0, 2.4 Hz, 1H), 3.45 (dd, *J* = 10.0, 7.2 Hz, 1H), 3.09 (bs, 1H), 2.29–2.37 (m, 1H), 1.88–1.98 (m, 1H), 1.71–1.79 (m, 1H), 1.12 (d, *J* = 6.8 Hz, 3H), 0.94 (d, *J* = 6.8 Hz, 3H), 0.90 (s, 18H), 0.82 (d, *J* = 7.2 Hz, 3H), 0.09 (s, 3H), 0.07 (s, 3H), 0.04 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 139.4, 115.7, 76.8, 76.7, 66.1, 40.9, 40.8, 39.7, 26.33, 26.32, 18.7, 18.5, 18.4, 15.4, 13.0, –3.9, –4.2, –4.9, –5.0; IR (neat) 3501, 2959, 2932, 2887, 2859, 1472, 1464, 1390, 1362, 1257, 1084, 1024, 1006, 913, 837, 776, 672 cm^{–1}; HRMS (ESI) *m/z* for C₂₃H₅₁O₃Si₂ [M+H]⁺ calcd 431.3377, found 431.3371.

(2Z,4E,6S,7S,8R,9R,10S,11R,12R)-9,11,13-tris((tert-butyldimethylsilyl)oxy)-7-hydroxy-6,8,10,12-tetramethyltrideca-2,4-dienamide (**8**)

A 50-mL, pear-shaped flask equipped with a rubber septum and argon inlet needle was charged with alcohol **19** (600 mg, 1.4 mmol) and anhydrous CH₂Cl₂ (15 mL). The solution was cooled to –78 °C and 2,6-lutidine (300 mg, 2.8 mmol) was added. After 10 min, *tert*-butyldimethylsilyl trifluoromethanesulfonate (555 mg, 2.1 mmol) was added at –78 °C. The reaction mixture was allowed to warm to ambient temperature and stirred for 8 h. The reaction was quenched with a saturated solution of NaHCO₃ (5 mL) and stirred for 1 h. Brine (5 mL) was added, the organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3 × 5 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification of the crude product was performed by flash column chromatography (gradient elution, hexane:Et₂O = 500:1 to 50:1), which provided TBS ether **32** (708 mg, 93% yield) as a

colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 5.98 (ddd, J = 18.0, 10.8, 8.0 Hz, 1H), 4.93–4.99 (m, 2H), 3.76 (dd, J = 4.0, 4.0 Hz, 1H), 3.67 (dd, J = 10.0, 5.2 Hz, 1H), 3.57 (dd, J = 6.8, 2.4 Hz, 1H), 3.39 (dd, J = 10.0, 8.0 Hz, 1H), 2.38–2.45 (m, 1H), 1.73–1.82 (m, 2H), 1.04 (d, J = 6.8 Hz, 3H), 0.91 (s, 9H), 0.90 (d, J = 6.8 Hz, 3H), 0.89 (s, 18H), 0.81 (d, J = 7.2 Hz, 3H), 0.10 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.043 (s, 3H), 0.039 (s, 3H).

A stream of ozone in O_2 was bubbled through a solution (initially light red, with Sudan III as the indicator) of TBS ether **32** (270 mg, 0.5 mmol) in dichloromethane (4 mL) and MeOH (1 mL) at -78°C until the light red solution became colorless. The solution was sparged with nitrogen to remove any excess ozone, then dimethylsulfide (5 mL) was added at -78°C . The reaction mixture was allowed to warm to ambient temperature and stirred for 24 h. The reaction mixture was filtrated through a pad of Celite. The solution was concentrated under reduced pressure. Purification of the crude product was performed by flash column chromatography (gradient elution, hexane: Et_2O = 100:1 to 10:1), which provided aldehyde **10** (240 mg, 88% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 9.82 (d, J = 1.6 Hz, 1H), 3.90 (dd, J = 6.4, 2.0 Hz, 1H), 3.81 (dd, J = 4.0, 3.2 Hz, 1H), 3.57 (dd, J = 10.4, 6.8 Hz, 1H), 3.39 (dd, J = 10.0, 6.8 Hz, 1H), 2.59 (qdd, J = 7.2, 1.6, 1.6 Hz, 1H), 1.79–1.93 (m, 2H), 1.13 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.894 (s, 9H), 0.89 (s, 9H), 0.87 (d, J = 7.2 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H), 0.10 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H).

Crystalline $(^d\text{Ipc})_2\text{BH}$ (286 mg, 1.0 mmol) was weighed into a round bottom flask containing a stir bar in a glove box. (Note: The crystalline borane should be crushed and pulverized to fine powder with a glass rod in order to ensure efficient allene hydroboration). The flask was capped with a rubber septum and removed from the glove box and placed in a cold bath (0°C). Ether (1.5 mL) was added slowly to the flask and the mixture (suspension) was cooled to 0°C . Racemic 1-stannyl-1,2-butadiene (344 mg, 1.0 mmol) was added neat via a microliter syringe. This mixture was stirred for 5 h at 0°C , during which time the solid $(^d\text{Ipc})_2\text{BH}$ dissolved to leave a colorless solution. The reaction mixture was cooled to -78°C and aldehyde **10** (218 mg in 500 μL dry ether, 0.4 mmol) was added dropwise to the reaction mixture via a microliter syringe at -78°C . The cold bath was removed and the mixture was allowed to warm to ambient temperature and stirred for 24 h. The reaction was cooled to 0°C . To the 0°C mixture was added saturated NaHCO_3 (1.0 mL) followed by slow addition of 30% H_2O_2 (2.0 mL). The reaction was stirred vigorously for ~5 h at room temperature. Brine (5 mL) was added, the organic layer was separated and the aqueous layer was extracted with Et_2O (3×5 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification of the crude product was performed by flash column chromatography (silica gel neutralized with 1% Et_3N in hexane; gradient elution, hexane: Et_2O = 100:1 to 10:1), which provided stereoheptad **33** (280 mg, 78% yield; $\text{ds} > 15:1$) as a colorless oil, contaminated with small amounts of isopinocampheol. This intermediate was used directly in the following reaction without future purification: ^1H NMR (400 MHz, CDCl_3) δ 6.06 (dd, J = 19.2, 6.8 Hz, 1H), 5.95 (d, J = 19.2 Hz, 1H), 3.69–3.81 (m, 4H), 3.49 (bs, 1H), 3.43 (dd, J = 10.0, 8.4 Hz, 1H), 2.22–2.30 (m, 1H), 1.98–2.05 (m, 1H), 1.76–1.88 (m, 2H), 1.41–1.58 (m, 6H), 1.25–1.34 (m, 6H), 0.58–0.99 (m, 54H), 0.134 (s, 3H), 0.13 (s, 3H), 0.09 (s, 3H), 0.07 (s, 3H), 0.044 (s, 3H), 0.040 (s, 3H).

To a mixture of iodide **11a**¹³ (12 mg, 60 μmol), vinyl stannane **33** (45 mg, 50 μmol), tris-(dibenzylideneacetone)-dipalladium(0) (2.3 mg, 2.5 mmol) and triphenylarsine (6 mg, 20 μmol) was added NMP (1.0 mL, freshly degassed by several freeze-thaw cycles under Ar). The resultant suspension was protected from light, warmed to 60°C and stirred for 12 h. Then the reaction mixture (brown) was cooled to ambient temperature and partitioned between EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3×3 mL). The

combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification of the crude product was performed by flash column chromatography (gradient elution, hexane:EtOAc = 20:1 to 1:2), which provided **8** (21 mg, 61%) as a colorless oil: $[\alpha]_{\text{D}}^{29.2} = -12.5^\circ$ (c 0.88, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.41 (dd, $J = 15.2, 11.2$ Hz, 1H), 6.50 (dd, $J = 11.6, 11.6$ Hz, 1H), 6.19 (dd, $J = 15.6, 8.0$ Hz, 1H), 5.53 (d, $J = 11.2$ Hz, 1H), 5.39 (bs, 1H), 5.27 (bs, 1H), 3.87 (d, $J = 8.8$ Hz, 1H), 3.79 (dd, $J = 6.8, 2.0$ Hz, 1H), 3.73 (dd, $J = 4.8, 4.4$ Hz, 1H), 3.69 (dd, $J = 10.0, 5.2$ Hz, 1H), 3.61 (s, 1H), 3.43 (dd, $J = 10.0, 8.0$ Hz, 1H), 2.39–2.48 (m, 1H), 1.97–2.05 (m, 1H), 1.76–1.87 (m, 2H), 1.02 (d, $J = 7.2$ Hz, 3H), 1.00 (d, $J = 6.8$ Hz, 3H), 0.95 (d, $J = 7.2$ Hz, 3H), 0.92 (d, $J = 6.8$ Hz, 3H), 0.915 (s, 9H), 0.903 (s, 9H), 0.896 (s, 9H), 0.15 (s, 3H), 0.14 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H), 0.044 (s, 3H), 0.041 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.9, 148.1, 143.3, 126.5, 117.8, 81.4, 75.8, 75.3, 65.1, 42.2, 41.4, 41.0, 35.1, 26.6, 26.5, 26.3, 19.0, 18.7, 18.6, 16.9, 14.9, 13.0, 12.3, –2.7, –2.9, –3.1, –3.8, –5.0; IR (neat) 3501, 2958, 2931, 2859, 1668, 1593, 1464, 1389, 1323, 1257, 1086, 1027, 1004, 836, 775 cm^{-1} ; HRMS (ESI) m/z for $\text{C}_{35}\text{H}_{74}\text{NO}_5\text{Si}_3$ $[\text{M}+\text{H}]^+$ calcd 672.4875, found 672.4869.

(2Z,4E,6S,7S,8R,9R,10S,11R,12R)-9,11,13-tris((*tert*-butyldimethylsilyl)oxy)-7-hydroxy-2,6,8,10,12-pentamethyltrideca-2,4-dienamide (9)

To a mixture of iodide **11b**^{6a} (13 mg, 60 μmol), vinyl stannane **33** (45 mg, 50 μmol), tris-(dibenzylideneacetone)-dipalladium(0) (2.3 mg, 2.5 μmol) and triphenylarsine (6 mg, 20 μmol) was added NMP (1.0 mL, freshly degassed by several freeze-thaw cycles under Ar). The resultant suspension was protected from light, warmed to 60 $^\circ\text{C}$ and stirred for 12 h. The reaction mixture (brown) was cooled to ambient temperature and partitioned between EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3×3 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification of the crude product was performed by flash column chromatography (gradient elution, hexane:EtOAc = 20:1 to 1:2), which provided **9** (23 mg, 61%) as a colorless oil: $[\alpha]_{\text{D}}^{29.2} = +11.2^\circ$ (c 0.82, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 6.74 (dd, $J = 15.2, 10.8$ Hz, 1H), 6.24 (d, $J = 10.8$ Hz, 1H), 5.93 (dd, $J = 15.2, 8.0$ Hz, 1H), 5.72 (bs, 1H), 5.54 (bs, 1H), 3.83 (d, $J = 9.2$ Hz, 1H), 3.79 (dd, $J = 6.8, 2.0$ Hz, 1H), 3.71 (dd, $J = 4.8, 4.8$ Hz, 1H), 3.69 (dd, $J = 10.0, 4.8$ Hz, 1H), 3.67 (s, 1H), 3.42 (dd, $J = 10.0, 8.0$ Hz, 1H), 2.29–2.38 (m, 1H), 1.97–2.05 (m, 1H), 1.95 (d, $J = 0.8$ Hz, 3H), 1.73–1.86 (m, 2H), 1.01 (d, $J = 7.2$ Hz, 3H), 0.95 (d, $J = 6.8$ Hz, 3H), 0.94 (d, $J = 7.2$ Hz, 3H), 0.92 (d, $J = 6.8$ Hz, 3H), 0.91 (s, 9H), 0.90 (s, 9H), 0.89 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H), 0.042 (s, 3H), 0.038 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 117.8, 143.2, 135.2, 128.8, 126.6, 81.3, 75.8, 75.3, 65.1, 42.2, 41.4, 41.0, 35.0, 26.6, 26.5, 26.3, 21.2, 19.0, 18.7, 18.6, 17.2, 14.9, 13.0, 12.3, –2.7, –2.9, –3.1, –3.8, –4.95, –4.96; IR (neat) 3368, 2958, 2931, 2859, 1662, 1599, 1464, 1386, 1257, 1086, 1030, 836, 775 cm^{-1} ; HRMS (ESI) m/z for $\text{C}_{36}\text{H}_{76}\text{NO}_5\text{Si}_3$ $[\text{M}+\text{H}]^+$ calcd 686.5031, found 686.5027.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support provided by the NIH (GM038436) and a predoctoral fellowship to M.C. from Eli Lilly is gratefully acknowledged.

Reference

1. Sensi P, Margalith P, Timbal M. *Farmaco Ed. Sci.* 1959; 14:146. For a recent review, see Floss HG, Yu TW. *Chem. Rev.* 2005; 105:621. [PubMed: 15700959]
2. Porter JR, Ge J, Lee J, Normant E, West K. *Curr. Top. Med. Chem.* 2009; 9:1386. [PubMed: 19860734]
3. For total synthesis of rifamycin S, see; Nagaoka H, Rutsh W, Schmid G, Iio H, Johnson MR, Kishi Y. *J. Am. Chem. Soc.* 1980; 102:7962.. Iio H, Nagaoka H, Kishi Y. *J. Am. Chem. Soc.* 1980; 102:7965.. Nagaoka H, Kishi Y. *Tetrahedron.* 1981; 37:3873.. Kishi Y. *Pure Appl. Chem.* 1981; 53:1163.
4. For selected syntheses of the ansa chain of rifamycin S: Corey EJ, Hase T. *Tetrahedron Lett.* 1979; 20:335.. Masamune S, Imperiali B, Garvey DS. *J. Am. Chem. Soc.* 1982; 104:5528.. Hanessian S, Pougny J-R, Bossenkool IK. *J. Am. Chem. Soc.* 1982; 104:6164.. Still WC, Barrish JC. *J. Am. Chem. Soc.* 1983; 105:2487.. Fraser-Reid B, Magdzinski L, Molino B. *J. Am. Chem. Soc.* 1984; 106:731.. Danishefsky SJ, Myles DC, Harvey DF. *J. Am. Chem. Soc.* 1987; 109:862.. Roush WR, Palkowitz AD. *J. Am. Chem. Soc.* 1987; 109:953.. Ziegler FE, Carn WT, Kneisly A, Stirchak EP, Wester RT. *J. Am. Chem. Soc.* 1988; 110:5442.. Paterson I, McClure CK, Schumann RC. *Tetrahedron Lett.* 1989; 30:1293.. Roush WR, Palkowitz AD, Ando K. *J. Am. Chem. Soc.* 1990; 112:6348.. Miyashita M, Yoshihara K, Kawamine K, Hoshino M, Irie H. *Tetrahedron Lett.* 1993; 34:6285.. Chenevert R, Rose YS. *J. Org. Chem.* 2000; 65:1707. [PubMed: 10750492] . Harada T, Egusa T, Igarashi Y, Kinugasa M, Oku A. *J. Org. Chem.* 2002; 67:7080. [PubMed: 12354003]
5. Matsuda S, Adachi K, Matsuo Y, Nukina M, Shizuri Y. *J. Antibiot.* 2009; 62:519. [PubMed: 19662086]
6. For total syntheses of saliniketals A and B, two closely related analogs of salinisporamycin, see: Paterson I, Razzak M, Anderson EA. *Org. Lett.* 2008; 10:3295. [PubMed: 18578531] . Yadav JS, Hossain SS, Madhu M, Mohapatra DK. *J. Org. Chem.* 2009; 74:8822. [PubMed: 19873991] . Liu J, De Brabander JK. *J. Am. Chem. Soc.* 2009; 131:12562. [PubMed: 19722715]
7. Rateb ME, Houssen WE, Arnold M, Abdelrahman MH, Deng H, Harrison WTA, Okoro CK, Asenjo JA, Andrews BA, Ferguson G, Bull AT, Goodfellow M, Ebel R, Jaspars M. *J. Nat. Prod.* 2011; 74:1491. [PubMed: 21553813]
8. (a) Hoffmann RW. *Angew. Chem., Int. Ed. Engl.* 1987; 26:489.(b) Hoffmann RW, Dahmann G, Andersen MW. *Synthesis.* 1994; 629
9. (a) Roush WR, Halterman RL. *J. Am. Chem. Soc.* 1986; 108:294.(b) Roush WR, Ando K, Powers DB, Palkowitz AD, Halterman RL. *J. Am. Chem. Soc.* 1990; 112:6339.
10. Masamune S, Choy W, Petersen JS, Sita LR. *Angew. Chem., Int. Ed. Engl.* 1985; 24:1.
11. Chen M, Roush WR. *J. Am. Chem. Soc.* 2012; 134:3925. [PubMed: 22332989]
12. Chen M, Roush WR. *J. Am. Chem. Soc.* 2011; 133:5744. [PubMed: 21449594] For selected synthetic applications of reagent (*S*)-*E*-4, see: Chen M, Roush WR. *Org. Lett.* 2012; 14:426. [PubMed: 22148850] . Chen M, Roush WR. *Org. Lett.* 2012; 14:1880. [PubMed: 22409510] . For a related 9-BBN derived reagent that gives (*Z*)-vinylstannane products, see: Yamamoto Y, Yatagai H, Maruyama K. *J. Am. Chem. Soc.* 1981; 103:3229.. Yamamoto Y, Maruyama K, Komatsu T, Ito W. *J. Org. Chem.* 1986; 51:886.
13. (a) Ma S, Lu X, Li Z. *J. Org. Chem.* 1992; 57:709.(b) Buynak JD, Vogeti L, Chen H. *Org. Lett.* 2001; 3:2953. [PubMed: 11554816]
14. (a) Choy N, Shin YS, Nguyen PQ, Curran DP, Balachandran R, Madiraju C, Day BW. *Org. Lett.* 2002; 4:4443. [PubMed: 12465908] (b) Izgu EC, Burns AC, Hoyer TR. *Org. Lett.* 2011; 13:703. [PubMed: 21244047]
15. (a) Brown HC, Bhat KS. *J. Am. Chem. Soc.* 1986; 108:293.(b) Ramachandran PV, Srivastava A, Hazra D. *Org. Lett.* 2007; 9:157. [PubMed: 17192109] (c) Waetzig JD, Hanson PR. *Org. Lett.* 2008; 10:109. [PubMed: 18062695]
16. (a) Guo J, Duffy KJ, Stevens KL, Dalko PI, Roth RM, Hayward MM, Kishi Y. *Angew. Chem., Int. Ed.* 1998; 37:187.(b) Zhou W, Jimenez M, Jung W-H, Camarco DP, Balachandran R, Vogt A, Day BW, Curran DP. *J. Am. Chem. Soc.* 2010; 132:9175. [PubMed: 20545347]

17. (a) Cherest M, Felkin H, Prudent N. *Tetrahedron Lett.* 1968; 18:2199.(b) Anh NT, Eisenstein O. *Nouv. J. Chim.* 1977; 1:61.
18. Roush WR. *J. Org. Chem.* 1991; 56:4151.
19. For selected examples, see: Roush WR, Palkowitz AD, Palmer MJ. *J. Org. Chem.* 1987; 52:316.. Brown HC, Bhat KS, Randad RS. *J. Org. Chem.* 1989; 54:1570.. Kim H, Ho S, Leighton JLJ. *Am. Chem. Soc.* 2011; 133:6517.. Roush WR, Trost BM. *Comprehensive Organic Synthesis*. 1991; Vol. 2:1.Pergamon PressOxford
20. The conformations of aldehydes **13**, **23**, **24** and **25** in transition states **TS-1** through **TS-5** are drawn in such a way to minimize gauche pentane interactions. See, for example, Hoffman RW. *Angew. Chem. Int. Ed. Engl.* 1992; 31:1124.
21. (a) Stille JK. *Angew. Chem., Int. Ed. Engl.* 1986; 25:508.(b) Farina V, Krishnamurthy V, Scott WJ. *Org. React.* 1997; 50:1.
22. The spectroscopic and physical properties (e.g., ^1H NMR, ^{13}C NMR, IR, mass spectrum and/or C,H analysis) of all new compounds were fully consistent with the assigned structures. Yields refer to chromatographically and spectroscopically homogeneous materials (unless noted otherwise). Experimental procedures and tabulated spectroscopic data for other new compounds are provided in the Supporting Information

Figure 1.
Structures of chaxamycins A and D, salinisporamycin and rifamycin S

Figure 2.
Strategy for synthesis of the *anti,anti*-stereotriad **7**

Figure 3.
Retrosynthetic analysis of stereoheptads **8** and **9**

Scheme 1.
Synthesis of Aldehyde **13**

Scheme 2.
Crotylboration Reactions of Aldehyde **13**

Scheme 3.

Intrinsic Diastereofacial Selectivity of Chiral Aldehydes Related to **13** is Dependent on Stereochemistry of the Aldehyde Substrate

Scheme 4.
Completion of the Syntheses of **8** and **9**